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ity of only 2%. 36 patients were discharged from the ED with a BNP level > 400 pg/ml.
The 90 days mortality was 9% in this group, while patients discharged from the ED with a
BNP level < 400 pg/ml had 0% mortality at 90 days. Patients who were discharged home
from the ED actually had higher BNP levels than those admitted (976 versus 767, p=0.6).
Using regression analysis, ED doctor’s intention to admit or discharge a patient had no
influence on their 90 day mortality, while the BNP level was a strong predictor of 90 day
mortality. Conclusion: In patients presenting to the ED with heart failure, there is a strong
disconnect between the perceived severity of CHF by ED physicians and severity as
determined by BNP levels. The results of this study strongly suggests that BNP levels will
aid physicians in making appropriate triage decisions about whether to admit or dis-
charge patients. This should avoid prolonged stays in the ED, unnecessary hospitaliza-
tions, inappropriate discharges home and lead to better patient care.
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Background: The COMET study reported a survival benefit for Carvedilol (C), a β1, β2
and α1 blocking agent, versus Metoprolol (M), a β1 selective blocker, in 3029 patients
(pts) (NYHA class II-IV, LVEF < 35%) with chronic heart failure (HF) followed-up for 46-74
months. While withdrawal of β-blockade (BB) is associated to worsening HF and arrhyth-
mias, only limited information exists on exchanging BB in pts with HF.
Methods: At the end of COMET, study BB therapy in pts with stable HF was to be
stopped without unblinding and down-titration and immediately replaced by open BB at a
dose equivalent to half of the study dose of pts. Thereafter, up-titration to maximum-toler-
ated or target BB dose was recommended. Pts were followed for 30 days for adverse
events.
Results: 1429 pts (47.2%) completed COMET on study BB (C 41 ± 15 mg, M 82 ± 30
mg). 1321 (92.4%) were subsequently switched to a post-study BB (1014 pts, 76.8%, to
C; 201, 15.2%, to M and 102, 7.7%, to bisoprolol), while 108 pts (7.6%) withdrew BB. Pts
staying on the same BB (8.7% on C, 7.4% on M) reported less adverse events than pts
switched to a different BB (15.1% from C to M, 14.1% from M to C) or those who with-
drew BB (22.2%). Most events occurred in the first week after the transition. The rate of
serious events was lower in pts who stayed on C (2.1%) or on M (3.2%), or in pts chang-
ing from M to C (3.1%), while higher in those switched from C to M (9.4%) or withdrawing
BB (11.1%). Nine pts (0.6%) died, 2 (0.2%) on C, 5 (2.5%) on M and 2 (1.9%) not receiv-
ing open BB. HF related events were more frequent in those switching from C to M
(4.7%; 4.7% serious) than in pts changing from M to C (2.3%; 1.5% serious). Bradycardia
and hypotension were reported in < 1% of pts. Pts on M who were switched to a reduced
dose of C (35%) showed a rate of HF events similar to those patients staying on C, but
lower than those changing to fully equivalent dose C (65%).
Conclusion: The exchange of BB without down-titration is a practical, safe and well-tol-
erated strategy in stable HF. The transition from M to a reduced dose of C is associated
with the lowest rate of serious and HF related events. Pts on M can be safely switched to
C to benefit from the survival advantage demonstrated in the COMET study.
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Background: Percutaneous closure of a patent foramen ovale (PFO) is an alternative to
medical or surgical prevention of recurrent embolism in patients with presumed PFO
mediated paradoxical embolism. Risk factors for recurrence after successful PFO closure
have not been completely elucidated yet.
Methods: We followed 299 patients with presumed PFO mediated paradocixal embolism
after percutaneous PFO closure for a total of 662 patient-years (mean follow-up: 2.2
years, range 0.2 – 8.5 years), assessing postprocedural shunt, recurrent embolic events
and device-related morbidity. Freedom of recurrence was calculated according to the
Kaplan-Meier method. Predictors of recurrence were calculated using a Cox proportional
hazard model.
Results: Twenty recurrent embolic events were observed (14 transient ischemic attacks,
5 events of peripheral embolism, 1 stroke), resulting in an actuarial recurrence rate of
3.8% (95% CI 1.7-6.4%) at 1 year, 7.9 (95% CI 4.9-12.6) at 2 years, and 8.7 (95% CI 5.5-
13.7%) at 4 years. Univariate predictors of recurrence were age at implantation > 60
years (hazard ratio 2.7, 95% CI 1.1-6.5), cardiovascular risk factors (hazard ratio 1.5 for
every additional factor, 95% CI 1.05-2.1), and most importantly the number of embolic
events prior to PFO closure (> 2 events: hazard ratio 4.1, 95% CI 1.7-9.8). Since patients
with multiple embolic events prior to PFO closure were older, only the cardiovascular risk
profile and > 2 events prior to PFO closure remained significant predictors of recurrence
in a multivariate Cox proportional hazard analysis. There was no relation between recur-
rence rate and atrial septal anatomy (PFO with or without atrial septal aneurysm), gen-
der, residual shunt after 6 months, type or size of device, and embolic index
event.Conclusions: Patients with > 2 thromboembolic events prior to device implantation
and patients with multiple cardiovascular risk factors are at increased risk for recurrence
of embolic events after PFO closure. These findings suggest that alternative mechanisms
in addition to paradoxical embolism may be present in this patient group.
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Background: Atrial flutter (AF) causes late postoperative (postop) morbidity in congeni-
tal heart patients. Sinoatrial node dysfunction (SAND) is often present but has not been
systematically evaluated as an AF risk factor. Methods: An institutionally approved retro-
spective single-center case-control study was performed. A computerized cardiology
database search identified patients aged <18 years with documented late AF (>6 months
postop; excluded if AF present at 1-6 months), and with >1 graded exercise test (GXT)
and/or 24-hour outpatient ambulatory ECG (Holter). AF-free controls were matched for
surgical procedures and year of birth ± 3 (median difference 0.4) years, with postop fol-
low-up at least equivalent to time points of first AF documentation in corresponding
cases. Non-AF heart rate (HR) data were extracted from all GXT (median 2/case, 2/con-
trol) and Holter (2/case, 1/control) records. Percent of maximum (max) predicted HR
achieved (%pred) was based on HRmax/(220 – age in years), where HRmax = max HR on
GXT or Holter. Data were analyzed using mixed linear regression for repeated measures.
Results: There was 85% concordance for 125 open heart operations in 42 case-control
pairs. AF onset in cases was at age 9.4±5.0 (mean±SD) years. Cases had lower average
HR, max HR, and %pred than controls (Table). Conclusion: Chronotropic reserve is
reduced but minimum HR is similar in AF patients versus controls. Chronotropic incom-
petence is thus an important feature of SAND in patients with late postop AF. 
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Background. Prior research is limited regarding the diagnostic and prognostic accuracy
of cardiac imaging modalities in women. The purpose of the current report was to exam-
ine 5-year mortality in 4,234 women and 6,898 men undergoing exercise or dobutamine
stress echocardiography at 3 hospitals.
Methods. Univariable and multivariable Cox proportional hazards models were used to
estimate time to cardiac death in this multicenter, observational registry.
Results. In this cohort of 11,132 patients, women had a greater frequency of cardiac risk
factors (p<0.0001). However, men more often had a history of coronary disease including
a greater frequency of stress-induced ischemia (p<0.0001). During the 5 years of follow-
up, 103 women and 226 men died from coronary artery disease (p<0.0001). From the
echocardiographic examination, estimates of left ventricular function (p<0.0001) and the
extent of ischemia (p<0.0001) noted during peak stress were highly predictive of cardiac
death. At 5 years, risk-adjusted survival was 99.4%, 97.6%, and 95% for exercising
women with no, single, and multiple vascular territories with ischemia (p<0.0001). For
women undergoing dobutamine stress, 5-year survival was 95%, 89%, and 86.6% for
those with no, 1, and 2 or 3 vessel ischemia (p<0.0001). For exercising men, cardiac
death at 5 years was higher at 1.1% to 4.5% for 0 to 3 vessel ischemia (p<0.0001). Sig-
nificantly worsening cardiac survival was noted for the 1,568 men undergoing dob-
utamine stress echocardiography (p<0.0001). No inducible ischemia was associated with
a 92% survival as compared with cardiac death rates of >16% for men with ischemia on
dobutamine stress echocardiography (p<0.0001).
Conclusion. Echocardiographic measures of inducible wall motion abnormalities and
global and regional left ventricular function are highly predictive of long term outcome for
women and men, alike.
Table
Minimum HR 
(Holter, beats/
min)
Average HR 
(Holter, beats/
min)
Max HR (GXT and 
Holter, beats/min)
%pred
Case (N=42) 55 ± 18 76 ± 10 146 ± 31 70 ± 15
Control 
(N=42)
56 ± 14 83 ± 17 169 ± 22 81 ± 10
P NS <0.001 <0.0001 <0.0001
